Last reviewed · How we verify
parsaclisinib
parsaclisinib is a Small molecule drug developed by Incyte Corporation. It is currently in discontinued development. Also known as: INCB050465.
Parsaclisinib is a medication being studied in a Phase 3 clinical trial for the treatment of Warm Autoimmune Hemolytic Anemia (wAIHA). It is being compared to a placebo in this trial, which is sponsored by Incyte Corporation.
At a glance
| Generic name | parsaclisinib |
|---|---|
| Also known as | INCB050465 |
| Sponsor | Incyte Corporation |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- parsaclisinib CI brief — competitive landscape report
- parsaclisinib updates RSS · CI watch RSS
- Incyte Corporation portfolio CI
Frequently asked questions about parsaclisinib
What is parsaclisinib?
Who makes parsaclisinib?
Is parsaclisinib also known as anything else?
What development phase is parsaclisinib in?
Related
- Manufacturer: Incyte Corporation — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: INCB050465
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing